Implementation and outcomes of a pharmacist-led collaborative drug therapy management program for oncology symptom management.
Cancer
Oncology
Pharmacist
Symptom
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
12
02
2021
accepted:
19
04
2021
pubmed:
28
4
2021
medline:
16
10
2021
entrez:
27
4
2021
Statut:
ppublish
Résumé
Nausea, vomiting, constipation, and diarrhea are common cancer and cancer therapy adverse effects. Pharmacists are uniquely positioned to optimize patient symptom control and minimize excess use of hospital resources, such as emergency department visits. Michigan Medicine oncology clinical pharmacists have been independently providing patient symptom management through a collaborative drug therapy management (CDTM) program which established guidelines for management of gastrointestinal toxicities (nausea, vomiting, diarrhea, and/or constipation) secondary to a patient's cancer diagnosis or treatment of the cancer. Patients were referred to the pharmacist by the treating oncologist or hematologist. From June 2019 to May 2020, there were a total of 62 patient referrals. Ten of the 62 referrals did not meet the CDTM inclusion criteria, resulting in 52 patients who were managed by the pharmacists. The total number of individual pharmacist visits was 136, with a median of 2.2 (range, 0-11) visits per patient referred. A total of 169 categorized pharmacist interventions were captured. Most interventions (100/169, 59.2%) were related to nausea/vomiting. Diarrhea-related and constipation-related interventions accounted for 10 (5.9%) and 13 (7.7%) of the total interventions, respectively. Most patients (36/52, 69.2%) had a reduction in the severity of their referral diagnosis symptom(s) based on Common Terminology Criteria for Adverse Events grading. The Michigan Medicine Pharmacist CDTM program allowed pharmacists to independently manage gastrointestinal toxicities of patients with cancer and improved patient symptom severity. The CDTM program has the opportunity to improve quality of care.
Identifiants
pubmed: 33905012
doi: 10.1007/s00520-021-06239-0
pii: 10.1007/s00520-021-06239-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6505-6510Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Rivera DR, Gallichio L, Brown J et al (2017) Trends in adult cancer-related emergency department utilization. JAMA Oncol 3(10):e172450
doi: 10.1001/jamaoncol.2017.2450
Centers of Medicaid and Medicare Services (2020) Measures Inventory Tool. Report generated
Hsu J, Donnelly JP, Moore JX et al (2018) National characteristics of emergency department visits by patients with cancer in the United States. Am J Emerg Med 36(11):2038–2043
doi: 10.1016/j.ajem.2018.03.025
Matzke GR, Moczygemba LR, Williams KJ et al (2018) Impact of a pharmacist–physician collaborative care model on patient outcomes and health services utilization. Am J Health-Syst Pharm 75(14):1039–1047
doi: 10.2146/ajhp170789
Ravichandran BR, Gillespie MW, Sparkes TM et al (2018) Collaborative practice agreement in solid organ transplantation. Int J Clin Pharm 40:474–479
doi: 10.1007/s11096-018-0604-1
Jackson K, Letton C, Maldonado A et al (2019) A pilot study to assess the pharmacy impact of implementing a chemotherapy-induced nausea or vomiting collaborative disease therapy management in the outpatient oncology clinic. J Oncol Pharm Pract 25(4):847–854
doi: 10.1177/1078155218765629
Hansen EA, Pietkiewicz JM, Blum BL (2016) Evaluation of the feasibility and utility of a pharmacist-centered collaborative drug therapy management program for oncology-based symptom management. J Pharm Pract 29(3):206–211
doi: 10.1177/0897190014557626
Sweiss K, Wirth SM, Sharp L et al (2018) Collaborative physician-pharmacist-managed multiple myeloma clinic improves guideline adherence and prevents treatment delays. J Oncol Pract 14(11):e674–e682
doi: 10.1200/JOP.18.00085
Valgus J, Jarr S, Schwartz R et al (2010) Pharmacist-led, interdisciplinary model for delivery of supportive care in the ambulatory cancer clinic setting. J Oncol Pract 6(6):e1–e4
doi: 10.1200/JOP.2010.000033
Valgus J, Faso A, Gregory K et al (2011) Integration of a clinical pharmacist into the hematology-oncology clinic at an academic medical center. Am J Health Syst Pharm 68(7):613–619
doi: 10.2146/ajhp100414
Hough S, McDevitt R, Nachar VR, et al (2021) Chemotherapy remote care monitoring program: integration of SMS text patient-reported outcomes in the electronic health record and pharmacist intervention for chemotherapy-induced nausea and vomiting. JCO Oncol Pract. https://doi.org/10.1200/OP.20.00639
Whitman A, DeGregory K, Morris A et al (2018) Pharmacist-led medication assessment and deprescribing intervention for older adults with cancer and polypharmacy: a pilot study. Support Care Cancer 4(26):4105–4113
doi: 10.1007/s00520-018-4281-3
Kutner JS, Blatchford PF, Taylor DH et al (2015) Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. JAMA Intern Med 175(5):691–700
doi: 10.1001/jamainternmed.2015.0289